IDEXX Laboratories, Inc. $IDXX Shares Sold by Weitz Investment Management Inc.

Weitz Investment Management Inc. cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 37.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 35,300 shares of the company’s stock after selling 21,500 shares during the period. IDEXX Laboratories comprises approximately 1.4% of Weitz Investment Management Inc.’s investment portfolio, making the stock its 26th biggest holding. Weitz Investment Management Inc.’s holdings in IDEXX Laboratories were worth $23,882,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Beacon Investment Advisory Services Inc. raised its position in shares of IDEXX Laboratories by 11.9% in the fourth quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after acquiring an additional 6,710 shares during the period. Nordea Investment Management AB raised its position in shares of IDEXX Laboratories by 114.1% in the fourth quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after acquiring an additional 8,845 shares during the period. NEOS Investment Management LLC raised its position in shares of IDEXX Laboratories by 82.7% in the third quarter. NEOS Investment Management LLC now owns 30,051 shares of the company’s stock worth $19,199,000 after acquiring an additional 13,599 shares during the period. Procyon Advisors LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter worth about $1,966,000. Finally, Diversified Trust Co. raised its position in shares of IDEXX Laboratories by 223.5% in the fourth quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock worth $2,841,000 after acquiring an additional 2,901 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Citigroup assumed coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Finally, UBS Group decreased their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Stock Up 0.2%

IDXX stock opened at $557.91 on Friday. The stock has a market capitalization of $44.01 billion, a P/E ratio of 41.08, a P/E/G ratio of 3.05 and a beta of 1.55. The firm has a 50-day simple moving average of $563.14 and a 200-day simple moving average of $628.16. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 52 week low of $506.91 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.